Effect of madopar combined with entacapone administration on plasma homocysteine level in patients with Parkinson's disease
- VernacularTitle:美多芭联合恩他卡朋治疗对帕金森病患者血浆同型半胱氨酸水平的影响
- Author:
Yan WU
;
Juan DU
;
Yisheng REN
- Publication Type:Journal Article
- Keywords:
Parkinson's disease;
madopar;
entacapone;
homocysteine
- From:
Journal of Clinical Neurology
2016;29(5):333-335
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of madopar combined with entacapone administration on plasma homocystein ( Hcy) level in patients with Parkinson's disease ( PD) .Methods Thirty healthy person were selected as a control group, 20 PD subjects with no levodopa ( LD) taking were as no treatment group, 63 subjects with madopar were as madopar group and 49 subjects with madopar combining entacapone were as combination group. Meanwhile levodopa concentration in peripheral blood and Unified PD Rating Scale Ⅲ ( UPDRSⅢ) score were measured.The plasma Hcy levels of all the researchers were detected.Results The L-dopa concentration in plasma of combination group was statistically significantly higher than that of madopar group ( P<0.05 ) .The score of UPDRSⅢscale of madopar group and combination group were significantly lower than that of madopar group ( all P<0.05).Compared with control group, the Hcy concentration in non-treatment group, madopar group and combination group were significantly increased ( all P<0.05 ) .And the Hcy concentration in madopar group was significantly higher than those in none treatment group and combination group ( all P<0.05 ) .Conclusion Madopar combined with entacapone therapy can significantly reduce plasma Hcy levels in patients with PD, which may be beneficial to the treatment of PD.
